Maximizing clozapine therapy: Managing side effects

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 3, 1998, Pages 38-43

  Lieberman, Jeffrey A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZATROPINE; BENZATROPINE MESILATE; CARBAMAZEPINE; CHLORPROMAZINE; CLONIDINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; METHYLPHENIDATE; PIRENZEPINE; PROPAFENONE; TRIHEXYPHENIDYL;

AGRANULOCYTOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; GASTROINTESTINAL DISEASE; HUMAN; HYPERSALIVATION; HYPOTENSION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; TACHYCARDIA; URINE INCONTINENCE; WEIGHT GAIN;

AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; INCIDENCE; LIVER DISEASES; RISK FACTORS; SCHIZOPHRENIA; SLEEP DISORDERS; TACHYCARDIA; URINARY INCONTINENCE; WEIGHT GAIN;

EID: 0031958032     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Lieberman JA. Atypical antipsychotic drags as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996;57(suppl 11):68-71
2. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
3. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;160(suppl 17):41-45
4. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752
5. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992;63:51-68
6. Baldessarini RJ, Frankenburg FR. A novel antipsychotic agent. N Eng J Med 1991;324:746-754
7. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329-338
8. Whitworth AB, Fleishhacker WW. Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 1995;9:21-27
9. Farde L, Wiesel FA, Nordstrom AL, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 1989;99:S28-S31
10. Heimer L. The Human Brain and Spinal Cord: Functional Neuroanatomy and Dissection Guide. New York, NY: Springer-Verlag; 1983:199-209
11. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine in tardive dyskinesia. Br J Psychiatry 1991;158:503-510
12. Peacock L, Solgaard T, Lublin H, et al. Clozapine versus typical antipsychotics: a retro- and prospective study of extrapyramidal side effects. Psychopharmacology (Berl) 1996;124:188-196
13. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318-322
14. Grohmann R, Ruther E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology (Berl) 1989;99:S101-S104
15. Stafferman A, Lieberman JA, Kane JM, et al. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247-261
16. Marinkovic D, Timotijevic I, Babinski T, et al. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:537-544
17. Naber D, Holzbach R, Perro C, et al. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 1992;160: 54-59
18. Keks NA. Minimizing the non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand Suppl 1996;94(suppl 389):18-24
19. Barnas C, Zwierzina H, Hummer M, et al. Granulocyte-marophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: a case report. J Clin Psychiatry 1992;53:245-247
20. Maes M, Bosnians E, Kenis G, et al. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997;26:221-225
21. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
22. Honigfeld G. The Clozapine National Registry System: forty years of risk management. J Clin Psychiatry Monograph 1996;14(2):29-32
23. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169: 483-488
24. Lieberman JA, Yunis J, Egen E, et al. HLA-B38, DR4, DQw3 and clozapine induced agranulocytosis. Arch Gen Psychiatry 1990;47:945-948
25. Hummer M, Kurz M, Bamas C, et al. Clozapine-induced transient white blood count disorders. J Clin Psychiatry 1994;55:429-432
26. Pisciotta V. Drug-induced agranulocytosis. Drugs 1978;15:132-143
27. Joffe RT, Post RM, Roy-Byrne PP, et al. Hematological effects of carbamazepine in patients with affective illness. Am J Psychiatry. 1985;142: 1196-1199
28. Oren R, Granat E, Shtrussberg S, et al. Clozapine-induced agranulocytosis treated with granulocyte macrophage colony stimulating factor. Br J Psychiatry 1993;162:686-687
29. Lamberti JS, Bellnier TJ, Schwarzkopf SB, et al. Filgrastim treatment of three patients with clozapine-induced agranulocytosis. J Clin Psychiatry 1995;56:256-259
30. Morstyn G, Burgess AW. Hemopoietic growth factors: a review. Cancer Res 1988;48:5624-5637
31. Burke M, Sebastian CS. Treatment of clozapine sedation. Am J Psychiatry 1993;150:1900-1901
32. Miller SC. Methylphenidate for clozapine sedation. Am J Psychiatry 1996;153:1231-1232
33. Rabinowitz T, Frankenburg FR, Centorrino F, et al. The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 1996;40:1132-1134
34. Ben-Aryeh H, Jungerman T, Szargel R, et al. Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol Psychiatry 1996;39:946-949
35. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine-induced sialorrhoea [letter]. Br J Psychiatry 1991;159:166
36. Marder SR. Adverse effects of clozapine. J Clin Psychiatry Monograph 1996;14(2):11-12
37. Crysdale WS. Drooling: experience with team assessment and management. Clin Pediatr (Phila) 1992;31:77-80
38. Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation [letter]. Lancet 1995;346:1034
39. Olsky M, Murray J. Dizziness and fainting in the elderly. Emerg Med Clin North Am 1990;8:295-307
40. Faber TS, Zehender M, Just H. Drug-induced torsade de pointes. Drug Saf 1994;11:463-476
41. Kus T, Dubuc M, Lambert C, et al. Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time. J Am Coll Cardiol 1990;16:1229-1237
42. Leo RJ, Kreeger JL, Kim KY. Cardiomyopathy associated with clozapine. Ann Pharmacother 1996;30:603-605
43. Koren W, Kreis Y, Duchowiczny K, et al. Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 1997;31:168-170
44. Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979;40:528-530
45. Holden JM, Holden UP. Weight changes with schizophrenia psychosis and psychotropic drug therapy. Psychosomatics 1970;11:551-561
46. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Drug Saf 1996;14:329-342
47. John JP, Chengappa KNR, Baker RW, et al. Assessment of changes in both weight and frequency of use of medications for the treatment of gastrointestinal symptoms among clozapine-treated patients. Ann Clin Psychiatry 1995;7:119-125
48. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical revelance. Am J Psychiatry 1992;149:68-72
49. Curzon G, Gibson EL, Oluysmi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 1997;18:21-25
50. Toth P, Frankerburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994;39:236-238
51. Kando JC, Tohen M, Castillo J, et al. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994;55: 255-257
52. Hummer M, Kurz M, Kurzthaler I, et al. Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997;17:314-317
53. Fuller MA, Borovicka MC, Jaskiw GE, et al. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996;57:514-518
54. Van Putten T, Malkin MD, Weiss MS. Phenothiazine-induced stress incontinence. J Urol 1973;109:625-626
55. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985;103: 228-239
56. Breier A. Mechanism of action of clozapine. J Clin Psychiatry Monograph 1996;14(2):6-7
57. Casey DE. The relationship of pharmacology to side effect. J Clin Psychiatry 1997;58(suppl 10):55-62
58. Young CR, Longhurst JG, Bowers MB, et al. The expanding indications for clozapine. Exp Clin Psychopharmacol 1997;5:216-234
59. Buckley P, Thompson PA, Way L, et al. Substance abuse and clozapine treatment. J Clin Psychiatry 1994;55(suppl B):114-116
60. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine [letter]. Am J Psychiatry 1995;152:959
61. Albanese MJ, Khantzian EJ, Murphy SL, et al. Decreased substance use in chronically psychotic patients treated with clozapine [letter]. Am J Psychiatry 1994;151:780-781
62. Ratey JJ, Leveroni C, Kilmer D, et al. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry 1993;54:219-223
63. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-611
64. Spivak B, Mester R, Wittenberg N, et al. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin Neuropharmacol 1997;20:442-446
65. Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin Neuropharmacol 1995;18:S18-S24
66. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
67. Allebeck P, Wistedt B. Mortality in schizophrenia: a ten-year follow-up based on the Stockholm County Inpatient Register. Arch Gen Psychiatry 1986;43:650-653